

Drug Discovery and Development Forum 2016

Program outline






June 6-10, 2016

The New Center for Translational Biology
(CTB), RI-MUHC, Glen site

presented by:

McGill-CIHR
Drug Development
Training Program and the MUHC RI
CTB Drug Discovery Platform






| | | DAY 1: Monday, June 6, 2016 | |
|--------------------|---|---|-----------------|
| | | EDUCATIONAL SESSIONS | ROOM |
| 9:00-11:00 |  | Dr. Robert Hambalek INTRODUCTION TO HYPHENATED NMR TECHNIQUES: BIOCHEMICAL / BIOMEDICAL APPLICATIONS | ES1.5077 |
| 9:00- 11:00 |  | Dr. Min Fu ADVANCED MICROSCOPY FOR DRUG DISCOVERY | E01.5135 |
| 11:00-12:00 |  | Dr. Barry Bedell MRI AND PET OF RODENT BRAINS | EM3.2225 |
| 13:00-15:00 |  | Dr. Kurt Dejgaard PRACTICAL PROTEOMICS | ES1.5077 |
| 15:00-17:00 |  | Dr. Jeff Xia METABOLOMICS – FROM BASIC CONCEPTS TO PRACTICAL DATA ANALYSIS | EM3.2225 |

| | | | |
|---------------|---|---|--|
| | | DAY 2: Tuesday, June 7, 2016 | |
| | | Symposium I | |
| | | <u>Challenges in Brain Tumour Treatment and New Drug Discovery</u> | |
| 8:30 - 9:00 | | Breakfast | |
| 9:00 - 9:05 | | Welcome speech by Dr. Janusz Rak, Session Chair | |
| 9:05 - 9:45 |  | Dr. Nada Jabado, MD, PhD, McGill University, Canada Pediatric brain tumour initiation and progression: a tale of a histone tail | Biomarkers, tumour microenvironment and Drug Response |
| 9:45 - 10:25 |  | Dr. Janusz Rak, MD, PhD, McGill University, Canada Oncogenic regulation of exosomal communication pathways within the brain tumour microenvironment | |
| 10:25 - 10:35 | | Coffee break | |
| 10:35-11:15 |  | Dr. Monika Hegi, Lausanne University Hospital, Switzerland Implementation of biomarkers in glioblastoma trials | |
| 11:15 - 12:00 |  | Dr. Bernd Kaina, University of Mainz, Germany DNA repair and death signaling in brain tumor cells treated with alkylating drugs | |




| | | |
|---------------|---|--|
| 13:15 - 13:20 |  | Welcome speech by Dr. Bassam Abdulkarim, MD, PhD, Session Chair |
| 13:20- 14:05 |  | Dr. Eric Bouffet, MD The tortuous journey of temozolomide in paediatric neuro-oncology |
| 14:05-14:25 |  | Dr. George Shenouda, MD Neo-adjuvant temozolomide followed by hypofractionated accelerated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma |
| 14:25 – 14:45 |  | Dr. Bertrand Jean-Claude, McGill University, Canada Temozolomide: from non-targeted to targeted design |
| 14:45-14:50 | | Coffee break |
| 14:50 - 15:30 |  | Dr. Andrew Kung, MD, PhD, Columbia University, USA Clinical and preclinical considerations for neuro-oncology drug development” |
| 15:30 -16:10 |  | Dr. Douglas Jolly, Tocagen Inc, USA Development of Toca 511 (an investigational non-lytic, retroviral replicating vector) and Toca FC (extended-release of 5-fluorocytosine) |
| 16:10 - 16:45 | | Panel Discussion |


Current and new Drug Development

| | | | |
|---------------|---|--|---|
| | | DAY 3: Wednesday, June 8, 2016 | |
| | | Symposium II | |
| | | <u>Animal Models and Translational Research</u> | |
| 8:30 – 9:15 | | Breakfast | |
| 9:15 - 9:20 | | Welcome speech by Dr. Richard Kremer, Session Chair | |
| 9:20 - 10:00 |  | Dr. Andrew Kung, Columbia University, USA Use of genomics and patient-derived xenograft models to realize the promise of personalized cancer medicine | In vivo models, combinations and Drug Response |
| 10:00 - 10:40 |  | Dr. Paul Haluska, Merck Research Institute, USA Ovarian avatars: Of mice and (wo)men... and personalized therapy | |
| 10:40 - 11:20 |  | Dr. Marcel Bally, BC Cancer Agency, Canada Drug formulation strategies to capture the benefits of drug combinations arising from chemical synthetic lethal screens | |
| 11:30 - 12:00 | | Panel Discussion | |
| 12:00-13:00 | | Lunch break | |
| 13:00-13:05 | | Welcome Speech by Dr. John Dibattista, Session Chair | |

| | | | |
|---------------|---|--|--|
| 13:05-13:45 |  | <p>Dr. Uri Saragovi, McGill University, Canada Challenges in academic translational research</p> | Current and new Drug Development: translational research |
| 13:45 - 14:20 |  | <p>Dr. Rima Al-Awar, Ontario Cancer Institute, Canada Discovery and optimization of small molecule antagonists of the WD repeat-containing protein 5 (WDR5) and mixed-lineage leukemia 1 (MLL1)</p> | |
| 14:20-14:50 |  | <p>Dr. Maria Luz Jaramillo, National Research Council of Canada Antibody and ADC Development at NRC</p> | |
| 14:50 - 15:10 | | <p>Panel Discussion</p> | |
| 15:10-16:45 | | <p>Oral presentations by trainees</p> <p><i>Sylvester Jusu</i>, Department of Medicine, McGill "Inhibition of MAP kinase activity sensitizes ras-transformed keratinocytes to 1,25(OH)₂D₃ signaling"</p> <p><i>Martin Rupp</i>, Department of Medicine, McGill "Targeting MGMT inhibitors to EGFR overexpressing tumour cells: a new approach to potentiate temozolomide in refractory tumours"</p> <p><i>Jenna Giubilaro</i>, Department of Pharmacology, McGill "Investigating the interplay between GPCR Internalization and cellular signaling using a novel modulator of receptor trafficking"</p> <p><i>Faeghen Ghanbari</i>, Department of Surgery, McGill "Structural and functional characterization of a novel endogenous steroid, estradienolone (ED), in human pregnancy urine"</p> <p><i>Chiu-An Lo</i>, Center for Research in Neuroscience, McGill "Quantification of protein levels in single living cells"</p> | |

| | | | |
|---------------|---|--|--|
| | | DAY 4: Thursday, June 9, 2016 | |
| | | Symposium III | |
| | | Small-Molecule Inhibitors and New Approaches | |
| 8:30 - 9:15 | | Breakfast | |
| 9:15 - 9:20 | | Welcome speech by Dr. John DiBattista, Session Chair | |
| 9:20 - 10:00 |  | Dr. Alain Wagner, Centre National de Recherche Scientifique, France The living as reaction media: towards the development of chemo-activated therapeutic agents. | Anti-cancer drugs and Antibiotics |
| 10:00 -10:40 |  | Dr. Mildred Duncan-Avecedo, University of South Florida, USA Atypical protein kinase C inhibition in prostate cancer cells | |
| 10:40 - 11:20 |  | Dr. Nathanael Gray, Harvard Medical School, USA Targeting cancer with covalent inhibitors | |
| 11:20 - 12:00 |  | Dr. Karine Auclair, McGill University, Canada Drug design against antimicrobial resistance | |
| 12:00 – 12:30 | | Panel Discussion | |
| 13:30-16:00 | | Poster session & commercial exhibition | |
| 16:00-17:15 | | Award cocktail | |

| | | | |
|-------------|---|--|--|
| | | DAY 5: Friday, June 10, 2016 | |
| | | Symposium IV | |
| | | Advanced Imaging in Drug Discovery and Development | |
| 8:00-8:25 | | Breakfast | |
| 8:25-8:30 | | Welcome speech by Dr. Danuta Radzioch, Session Chair | |
| 8:30-9:15 |  | Dr. Pierre Chaurand, Université de Montréal, Canada Matrix and metal assisted laser desorption ionization for high spatial resolution imaging mass spectrometry of lipids from thin tissue sections. | Innovative imaging methods and technologies |
| 9:15- 10:00 |  | Dr. David Bonnel, Imabiotech, France MALDI Imaging application from preclinical to clinical stages | |
| 10:00-10:45 |  | Dr. Peter Metrakos , McGill University, Canada Mass Spectrometry Imaging: A surgeon's View | |

| | | | |
|---------------|---|--|--|
| 10:45 - 11:30 |  | Dr. Sébastien Blais-Ouellette, Photon ETC, Canada Advances in instrumentation and labels for highly multiplexed biological | |
| 11:30 - 11:45 | | Panel Discussion | |
| 11:45-12:00 | | closing statements: Dr. Danuta Radziok, Session Chair and Dr. Bertrand Jean-Claude, Director, CTB Drug Discovery Platform | |
| 13:0–16:00 | | CTB Drug Discovery Platform MSI Demonstration | |

A Special thanks to the proud corporate sponsors



MERCK

INNOVATIVE
MEDICINES
CANADA



MÉDICAMENTS
NOVATEURS
CANADA

WILEY



SIGMA-ALDRICH®



We Enable Science



**WISENT
BIOPRODUCTS**